Charles River Laboratories International, Inc.

NYSE:CRL

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

🔍 Research & Consulting

Location

United States

Market Cap

USD 7.71 B

Share Price

USD 156.68

Avg Daily Volume

900,854

Change (1 day)

0.56%

Change (1 year)

-22.47%

Change (YTD)

-15.12%

Charles River Laboratories International, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 28, 2025: USD 528.39 M

Charles River Laboratories International, Inc. EBITDA is USD 528.39 M for the Trailing 12 Months (TTM) ending June 28, 2025, a -47.48% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Charles River Laboratories International, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 29, 2024 was USD 1.01 B, a -5.76% change year over year.
Charles River Laboratories International, Inc. EBITDA for the Trailing 12 Months (TTM) ending July 01, 2023 was USD 1.07 B, a 18.97% change year over year.
Charles River Laboratories International, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 25, 2022 was USD 897.40 M, a 6.90% change year over year.
Charles River Laboratories International, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 26, 2021 was USD 839.46 M, a 35.80% change year over year.